JP2017526696A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526696A5
JP2017526696A5 JP2017512683A JP2017512683A JP2017526696A5 JP 2017526696 A5 JP2017526696 A5 JP 2017526696A5 JP 2017512683 A JP2017512683 A JP 2017512683A JP 2017512683 A JP2017512683 A JP 2017512683A JP 2017526696 A5 JP2017526696 A5 JP 2017526696A5
Authority
JP
Japan
Prior art keywords
group
cancer
alkyl
heterocyclyl
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526696A (ja
JP6767969B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048354 external-priority patent/WO2016036954A1/en
Publication of JP2017526696A publication Critical patent/JP2017526696A/ja
Publication of JP2017526696A5 publication Critical patent/JP2017526696A5/ja
Application granted granted Critical
Publication of JP6767969B2 publication Critical patent/JP6767969B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512683A 2014-09-05 2015-09-03 がんの処置における使用のためのpcafおよびgcn5阻害剤としての式(i)のフタラジン誘導体 Expired - Fee Related JP6767969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046756P 2014-09-05 2014-09-05
US62/046,756 2014-09-05
PCT/US2015/048354 WO2016036954A1 (en) 2014-09-05 2015-09-03 Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2017526696A JP2017526696A (ja) 2017-09-14
JP2017526696A5 true JP2017526696A5 (cg-RX-API-DMAC7.html) 2018-10-11
JP6767969B2 JP6767969B2 (ja) 2020-10-14

Family

ID=54266610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512683A Expired - Fee Related JP6767969B2 (ja) 2014-09-05 2015-09-03 がんの処置における使用のためのpcafおよびgcn5阻害剤としての式(i)のフタラジン誘導体

Country Status (5)

Country Link
US (1) US10155764B2 (cg-RX-API-DMAC7.html)
EP (1) EP3189049B1 (cg-RX-API-DMAC7.html)
JP (1) JP6767969B2 (cg-RX-API-DMAC7.html)
CN (1) CN107074824B (cg-RX-API-DMAC7.html)
WO (1) WO2016036954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
JP6598286B2 (ja) * 2014-12-05 2019-10-30 国立大学法人東京工業大学 チロシンの修飾方法
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック, インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN108196068B (zh) * 2018-01-29 2019-09-10 武汉大学 血管紧张素转化酶启动子区组蛋白乙酰化在制备改善胎源性成年骨质疏松症药物中的应用
KR102085758B1 (ko) * 2019-08-05 2020-03-06 연세대학교 산학협력단 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
JP2023511472A (ja) * 2019-10-29 2023-03-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二官能性化合物
EP4188383A4 (en) * 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
MX2023002942A (es) 2020-09-11 2023-05-22 Mirati Therapeutics Inc Formas cristalinas de un inhibidor de kras g12c.
TWI880049B (zh) * 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
CA3198885A1 (en) 2020-12-15 2022-06-23 Xiaolun Wang Azaquinazoline pan-kras inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022170952A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
EP4346815A4 (en) * 2021-05-27 2025-04-02 Schrödinger, Inc. HETEROCYCLIC COMPOUNDS AND METHODS OF USE
CN120112525A (zh) 2022-09-02 2025-06-06 奥龙医疗公司 用于治疗增殖性病症的作为kat2降解剂的哒嗪酮衍生物
CN119504796A (zh) * 2024-11-20 2025-02-25 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB808636A (en) * 1955-08-02 1959-02-11 Cassella Farbwerke Mainkur Ag Basically substituted heterocyclic compounds
JPS4931683A (cg-RX-API-DMAC7.html) * 1972-07-27 1974-03-22
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
CN1568187A (zh) * 2001-08-15 2005-01-19 Icos股份有限公司 2h-2,3-二氮杂萘-1-酮和其使用方法
WO2005099688A2 (en) * 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
EA014955B1 (ru) * 2004-06-30 2011-04-29 Янссен Фармацевтика Н. В. Производные фталазина в качестве ингибиторов parp
CN102918031A (zh) 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
KR101422725B1 (ko) * 2011-10-19 2014-07-25 한국화학연구원 신규한 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 mch 수용체-1 관련 질환의 예방 또는 치료용 약학적 조성물
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
US9200005B2 (en) * 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
JP2016519672A (ja) 2013-03-15 2016-07-07 ジェネンテック, インコーポレイテッド ブロモドメイン含有タンパク質brd7およびbrd9の阻害によるth2媒介性疾患の治療
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック, インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用

Similar Documents

Publication Publication Date Title
JP2017526696A5 (cg-RX-API-DMAC7.html)
JP2017530176A5 (cg-RX-API-DMAC7.html)
JP2017533250A5 (cg-RX-API-DMAC7.html)
JP2017525740A5 (cg-RX-API-DMAC7.html)
JP2019516757A5 (cg-RX-API-DMAC7.html)
JP2017537100A5 (cg-RX-API-DMAC7.html)
JP2019516759A5 (cg-RX-API-DMAC7.html)
JP2018501287A5 (cg-RX-API-DMAC7.html)
JP2018510851A5 (cg-RX-API-DMAC7.html)
JP2017533249A5 (cg-RX-API-DMAC7.html)
JP2017530984A5 (cg-RX-API-DMAC7.html)
JP2017533248A5 (cg-RX-API-DMAC7.html)
TWI373465B (en) Methods of administering pirfenidone therapy
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
JP2018507191A5 (cg-RX-API-DMAC7.html)
JP2016519072A5 (cg-RX-API-DMAC7.html)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2018505169A5 (cg-RX-API-DMAC7.html)
JP2010522194A5 (cg-RX-API-DMAC7.html)
EA202090419A1 (ru) Селективные ингибиторы инфламмасомы nlrp3
JP2012526143A5 (cg-RX-API-DMAC7.html)
JP2016510748A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
CN107250149A (zh) 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
PH12019502586B1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof